<DOC>
	<DOCNO>NCT00177671</DOCNO>
	<brief_summary>This study determine effectiveness combine escitalopram , venlafaxine , duloxetine donepezil , medication use Alzheimer 's disease , improve memory , concentration , attention , problem solve ability , reduce risk depressive relapse old individual depression .</brief_summary>
	<brief_title>Antidepressant Medication Plus Donepezil Treating Late-life Depression</brief_title>
	<detailed_description>The purpose research study learn combine antidepressant medication ( escitalopram , venlafaxine , duloxetine ) medication use Alzheimer 's Disease ( donepezil ) , elderly patient age 65 old major depression , help 1 ) improve and/or maintain memory , concentration , attention , problem solve ability ability balance checkbook , pay bill , use telephone , 2 ) reduce risk depressive symptom return . Study participation last two year . We aim investigate pharmacologic strategy improve stabilize cognitive function late-life depression minimize progression cognitive associate functional impairment . Cognitive impairment late-life depression adequately address previous intervention research , core feature illness , contribute markedly disability impaired quality life , overlook potentially critical target intervention . Data MTLD II study suggest treat depression normalize cognitive function may prevent progression . We test pharmacologic strategy involve cholinesterase inhibitor donepezil , combination maintenance antidepressant pharmacotherapy ( escitalopram , venlafaxine , duloxetine ) , improve maintain cognitive functioning functional competence elderly patient major depression . We hypothesize maintenance antidepressant pharmacotherapy combine donepezil superior maintenance antidepressant pharmacotherapy combine placebo/clinical management ( 1 ) improve cognitive performance ; ( 2 ) slow progression cognitive impairment decline functional competence . We plan recruit 200 patient age 65 current episode major depression . Those respond antidepressant pharmacotherapy citalopram , venlafaxine , duloxetine randomly assign double-blind basis one two 24-month treatment : 1 ) antidepressant pharmacotherapy plus donepezil/clinical management ; 2 ) antidepressant pharmacotherapy plus placebo/clinical management . For information relate study , please follow link : http : //clinicaltrials.gov/show/NCT00000377 http : //clinicaltrials.gov/show/NCT00178100</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Current episode major depression HRSD 17item score 15 high Must able speak English Willing discontinue psychotropics Availability family member/caregiver Hearing capacity adequate respond raise conversational voice Must formal diagnosis dementia Meets DSMIV criterion bipolar disorder , schizophrenia , schizoaffective disorder , psychotic disorder Alcohol/drug abuse within 12 month study entry History treatment nonadherence clinic protocol History nonresponse citalopram clinic protocol History nontolerance SSRI therapy</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Depression</keyword>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Cognitive</keyword>
	<keyword>Donepezil</keyword>
	<keyword>Memory</keyword>
	<keyword>Function</keyword>
	<keyword>Elderly</keyword>
	<keyword>Late-Life</keyword>
</DOC>